Dendritic cell-based cancer immunotherapies.
Because of their unique role in linking the innate and adaptive immune systems, dendritic cells (DCs) have been a logical focus for novel immunotherapies. However, strategies employing active immunization with ex vivo generated and antigen-pulsed DCs have shown limited efficacy in clinical trials. These past approaches did not take into account the complex interactions between cells of the innate immune system and DCs during DC maturation, antigen processing, and presentation to naïve T cells. By better understanding the natural sequence of events occurring in vivo during an effective immune response, we can tailor antitumor immunotherapeutic strategies to augment aspects of this response from the activation of innate immune cells to antigen uptake and DC maturation to priming of naïve T cells and, ultimately, to the establishment of antitumor immunity. Current DC vaccination strategies utilize a number of methods to recapitulate the cascade of events that culminate in a protective antitumor immune response.
Fujii
Shin-ichiro
S
Research Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology, Institute of Physical and Chemical Research, Yokohama RIKEN, Yokohama, Kanagawa 230-0045, Japan. fujiis@rcai.riken.jp
Takayama
Takuya
T
Asakura
Miki
M
Aki
Kaori
K
Fujimoto
Koji
K
Shimizu
Kanako
K
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D055611:Natural Killer T-Cells / Q000276:immunology / Q000378:metabolism; D009369:Neoplasms / Q000628:therapy*; D012333:RNA, Messenger / Q000276:immunology / Q000378:metabolism; D051193:Toll-Like Receptors / Q000276:immunology / Q000378:metabolism
D000951:Antigens, Neoplasm; D019013:CD40 Antigens; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D012333:RNA, Messenger; D051193:Toll-Like Receptors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor